Key Takeaway: Astellas has entered into a licensing agreement with 4D Molecular Therapeutics, paying $20 million upfront to utilize its viral vector technology for treating a rare monogenic eye disease. The total potential value of the deal could reach $962 million, indicating Astellas' commitment to expanding its capabilities in the ophthalmology sector.
Price reaction · baseline $14.45 (2023-09-21 close) · hit pre-market · clean, no other FDMT news in the window
day 0 close · peak
-3.7%
Market Sentiment Analysis
POSITIVE FACTORS
Astellas is expanding its portfolio in rare ophthalmology.
The deal with 4DMT could lead to significant financial gains.
The use of a viral vector for gene therapy shows innovative approaches.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
Full Press Release Details
Lei Lei Wu
News Reporter
Astellas will pay 4D Molecular Therapeutics $20 million upfront to use its viral vector for a rare monogenic eye disease in a deal worth up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Frequently Asked Questions
What is the total value of the Astellas and 4DMT deal?
The deal between Astellas and 4DMT could be worth up to $962 million.
How much is Astellas paying upfront to 4DMT?
Astellas will pay 4DMT $20 million upfront.
What type of disease is the viral vector targeting?
The viral vector is intended for a rare monogenic eye disease.
What technology is Astellas licensing from 4DMT?
Astellas is licensing a viral vector technology for gene therapy.